financetom
Business
financetom
/
Business
/
Why Photocopy Giant Xerox Shares Are Down Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Photocopy Giant Xerox Shares Are Down Today
Mar 6, 2024 10:41 AM

Xerox Holdings Corporation ( XRX )  shares are trading lower today.

Yesterday, Xerox announced its intention to offer, $300 million of convertible senior notes in a private placement to qualified institutional buyers.

The company expects to grant the initial purchasers of the Notes a 13-day option to purchase up to $45 million of additional notes.

The company also announced an increase in the maximum tender cap for 5.000% senior notes due 2025.

The company raised the maximum principal amount of its $750 million principal amount outstanding to $362 million from $94 million for 5.000% Senior Notes due 2025, which can be repurchased under its previously announced cash tender offer for the 2025 Notes. 

The terms of the previously announced cash tender offer by Xerox for its 3.800% senior notes due 2024 remain unchanged.

Xerox expects to use the net proceeds to fund the cost of the capped call transactions and for general corporate purposes.

Last month, Xerox reported a fourth-quarter sales decline of 9.1% Y/Y to $1.77 billion, missing the $1.79 billion estimate and adjusted EPS of $0.43, which fell short of the $0.52 expected.

The company witnessed equipment sales drop 17.3%, post-sale revenue down 5.8%, and guided FY24 revenue below consensus.

Price Action: XRX shares are down 9.21% at $17.06 on the last check Wednesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Vale expects research, innovation investments to top $400 million in coming years
Vale expects research, innovation investments to top $400 million in coming years
Sep 11, 2024
BELO HORIZONTE, Brazil, Sept 11 (Reuters) - Brazilian miner Vale expects to invest more than $400 million in research, development and innovation (RD&I) annually in the coming years, the firm's executive vice president of technical affairs told Reuters. In 2023, the company invested $447.8 million in RD&I. The idea is to keep it more or less on that scale, Rafael...
Dave & Buster's Shows Margin Upside in Q2 Amid Sales Struggle, Truist Says
Dave & Buster's Shows Margin Upside in Q2 Amid Sales Struggle, Truist Says
Sep 11, 2024
11:05 AM EDT, 09/11/2024 (MT Newswires) -- Dave & Buster's Entertainment (PLAY) has managed to show margin upside in Q2 amid its struggle with same-store sales, Truist said in a Tuesday note. PLAY's strong 2Q24 margin performance also renews our confidence in its ability to at least partially offset the impact of near-term SSS pressure with operating cost efficiencies, supporting...
Market Chatter: Hewlett Packard Enterprise Seeks $9.5 Billion Debt Package for Juniper Acquisition
Market Chatter: Hewlett Packard Enterprise Seeks $9.5 Billion Debt Package for Juniper Acquisition
Sep 11, 2024
11:06 AM EDT, 09/11/2024 (MT Newswires) -- Hewlett Packard Enterprise ( HPE ) is talking with investors on Wednesday on a potential $9.5 billion debt deal to support the acquisition of Juniper Networks, Bloomberg reported. Calls with potential bond investors started at 10 am New York time with JPMorgan Chase ( JPM ) coordinating the talks, and a bond offering...
Update: BriaCell Shares Surge After Reporting Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study
Update: BriaCell Shares Surge After Reporting Positive Data for Bria-IMT in Phase 2 Metastatic Breast Cancer Study
Sep 11, 2024
11:03 AM EDT, 09/11/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) BriaCell Therapeutics ( BCTX ) shares surged over 123% in recent Wednesday trading after it reported positive overall survival data in a phase 2 late-stage metastatic breast cancer study evaluating Bria-IMT in combination with an immune check point inhibitor. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved